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Abstract: Familial Mediterranean fever (FMF) is an autosomal recessive inflammatory disorder caused by mutations in the 
MEFV gene that encodes the pyrin protein. The disease is relatively common among people originating from the 
Mediterranean areas. The aim of this study was to determine the common MEFV gene mutations in 270 Palestinian patients 
diagnosed with FMF. The patients were screened for four common MEFV gene mutations namely, p.M694V, p.M694I, 
p.V726A, and p.E148Q using allele-specific polymerase chain reaction (AS-PCR). The results revealed that around 22% of the 
patients harbored two MEFV mutations, with the compound heterozygous forms being more prevalent than the homozygous 
ones. The most frequently encountered mutant allele was p.M694V which existed in around 12% of the tested chromosomes. 
The p.M694I, p.V226A and p.E148Q mutations were observed in around 9, 9 and 7% of the tested chromosomes, respectively. 
In about 29% of the patients only one mutant allele could be detected and around 49% of the patients did not show any of the 
investigated mutations. In conclusion, the four tested MEFV gene mutations have a significant contribution to FMF in the 
Palestinian population of Gaza strip. Screening for those mutations should be offered to FMF patients to confirm diagnosis and 
effect timely treatment. Further mutations analysis the MEFV gene should be conducted in this population in order to 
document additional MEFV mutations. 
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1. Introduction 
Familial Mediterranean fever (FMF; OMIM: 249100) is an 
autosomal recessive inflammatory disorder characterized by 
recurrent, self-limiting, episodes of fever and abdominal pain. 
If left untreated, amyloidosis and subsequent renal failure can 
occur in a significant fraction of the patients (Livneh et al., 
1999). 
Through analyses of MEFV gene three forms of FMF have 
been suggested. Patients with typical clinical features are 
defined as type I. Patients who present with renal 
amyloidosis without typical attacks of the disease have been 
defined as type II (Balci et al., 2002). Individuals who do not 
have any symptoms related to FMF but have at least two 
MEFV mutations are considered type III (Yigit et al., 2008). 
The disease is relatively common among people of 
Mediterranean origin especially, North African Jews, 
Armenians, Turks, and Arabs (Ben-Chetrit and Touitou, 2009) 
with a carrier frequency reaching up to 39% in certain 
populations (Booty et al., 2009). 
FMF is the result of mutations in MEFV gene which codes 
for the protein pyrin. The gene is located on chromosome 
16p13.3 and comprises 10 exons. MEFV is expressed 
predominantly in the granulocytes and its product, pyrin, 
participates in the inflammatory response (Shohat and 
Halpern, 2011).  
Over 30 disease-associated mutations have been identified 
in the MEFV, with the majority of mutations being missense 
changes clustering in exons 2 and 10 (Touitou et al., 2004). 
Molecular diagnosis of patients with FMF is usually initiated 
by targeted-mutation analysis through screening for the 
common mutations that are frequently observed in FMF 
cases (e.g., p.M694V, p.M694I, p.V726A, p.M680I, and 
p.E148Q). In most individuals suffering from FMF, analysis 
of those common mutations confirms the diagnosis (Kishida 
et al., 2014). 
The Gaza strip is a small area (365 km2) located in the 
south-western part of Palestine. It lies at the Mediterranean 
southeast coast. The strip is inhabited by around 1.9 million 
people.  
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This study was carried out to screen FMF-diagnosed 
Palestinian patients for the four common MEFV gene 
mutations: p.M694V, p.M694I, p.V726A and p.E148Q. 
2. Materials and Methods 
2.1. Patients 
The population of this descriptive study consisted of 270 
patients with an initial diagnosis of FMF type I. The patients 
were referred to our Genetic diagnosis unit by general 
pediatricians and internists from all over Gaza Strip. Clinical 
phenotypes are assigned according to the Tel-Hashomer 
criteria for diagnosis of FMF (Sari et al., 2014). The patients 
consisted of 150 males and 120 females. The age of the 
patients ranged from 5 to 15 years.  
2.2. Mutation Analysis 
Anticoagulated venous blood (~2 ml) was collected from 
each patient. Genomic DNA was prepared from peripheral 
blood lymphocytes using Wizard Genomic DNA Purification 
Kit (Promega, USA) according to the manufacturer's protocol. 
Extracted DNA was used in screening for the four selected 
mutations. Allele-specific PCR (AS-PCR) was employed for 
detecting the four mutations as previously described by other 
investigators (Ayesh et al., 2005; Mohammadnejad and 
Farajnia, 2013). PCR products were analyzed by 
electrophoresis in a 2% agarose gel containing ethidium 
bromide, and the results were documented using a gel 
documentation system. 
All the DNA samples were screened for p.M694V, 
p.M694I, p.V726A, and p.E148Q mutations. The rationale 
behind selecting those mutations is based on their common 
presence in FMF patients of Mediterranean origins. 
3. Results 
This study investigated four common MEFV gene 
mutations in 270 patients living in the Gaza strip region of 
Palestine. Among the FMF diagnosed patients, 150 (55.56%) 
were males and 120 (44.44%) were females. The age of the 
patients ranged from 5 to 15 years. 
Genotyping results showed that p.M694V was the most 
frequently encountered mutation where 64 (11.85%) of the 
tested 540 chromosomes harbored this mutation. The other 
three mutations; p.M694I, p.V726A, and p.E148Q, existed in 
9.07, 8.9 and 6.85% of the chromosomes, respectively (Table 
1). 
Around 49% (132/270) of the patients did not show any of 
the tested mutations, 78 (28.9%) had one mutation and 60 
(22.2%) had two mutations, of whom 24 were homozygous 
and 36 were compound heterozygous (Table 2). 
4. Discussion 
This work investigated four MEFV mutations in Gaza strip 
Palestinian patients with the initial diagnosis of FMF. The 
results revealed that the MEFV mutations, in one or two 
copies, were evident in about half of the patients. This 
mutation detection rate is comparable to that reported in 
other MEFV targeted mutation studies (e.g., Balci et al., 2002; 
Medlej-Hashim et al., 2005; Belmahi et al., 2012).  
The four tested mutations showed a trend, in terms of the 
frequency of mutant alleles, comparable to that reported in 
other Mediterranean populations (Touitou, 2001). 
Additionally, mutation p.M694V was the most frequent 
mutation and represented about 32% of the mutant alleles 
(Table 1). This mutation is also the most frequently seen 
mutation in FMF patients belonging to the four major 
Mediterranean (Armenians, Jews, Arabs and Turks) 
populations (e.g., Aksentijevich et al., 1999; Solak et al., 
2008; Belmahi et al., 2012). These observations indicate that 
common MEFV mutations are actually old and had 
descended from ancestors (founders) common to the four 
populations.  
Table 1. Distribution of MEFV mutations in tested patients. 
Mutation No. of chromosomes (%) % among the mutant alleles 
p.M694V 64 11.85 32.32 
p.M694I 49 9.07 24.75 
p.V726A 48 8.90 24.24 
p.E148Q 37 6.85 18.69 
Unknown 342 63.33 - 
Total 540 100  
Table 2. Genotypes distribution in the patients. 
Genotype No. of patients % Sub-total No. (%) 
p.M694I/p.M694I 12  4.44 
24 (8.88) 
p.V726A/p.V726A 6  2.22 
p.E148Q/p.E148Q 5 1.85 
p.M694V/ p.M694V 1 0.37 
p.M694V/ p.V726A 11  4.07 
36 (13.33) 
p.M694V/p.E148Q 8  2.96 
p.M694I/p.V726A 7 2.59 
p.M694V/p.M694I 4 1.48 
p.M694I/p.E148Q 3 1.11 
p.V726A/p.E148Q 3 1.11 
p.M694V/X* 39  14.44 
78 (28.90) 
p.V726A/X 15  5.60 
p.E148Q/X 13 4.80 
p.M694I/X 11  4.07 
X/X 132 48.89 132 (48.89) 
Total 270 100 270 (100) 
* X = Unknown 
Apart from importance in confirming the diagnosis, 
identification of MEFV mutations in FMF patients is 
essential for justifying colchicine treatment and predicting 
disease phenotype. Colchicine is the mainstay of treatment- it 
prevents attacks and relieves symptoms. Colchicine is also 
important in delaying the development of amyloidosis (Ozen, 
2004). Genotype-phenotype correlation studies have shown 
that mutation type is associated with clinical characteristics 
of the disease. The presence of p.M694V mutation, in either 
homozygous or heterozygous form, is usually associated with 
severe disease presentation (Majeed et al., 2002; 
Mohammadnejad and Farajnia, 2013; Ece et al., 2014; Uluca 
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et al., 2015). Likewise, p.V726A/p.V726A genotype predicts 
a poor clinical outcome (Majeed et al., 2002). On the other 
hand, p.M694I/p.M694I and p.E148Q/p.148Q genotypes are 
associated with milder disease forms (Majeed et al., 2002; 
Uluca et al., 2015).  
Assuming correct FMF diagnosis, observing patients with 
only one mutant MEFV allele and others without any 
detectable MEFV mutation, is suggestive for the presence of 
other MEFV mutations. Therefore, analysis of those samples 
for other known mutations and sequencing of the MEFV 
mutation-prone exons, such as exons 1,2,3,5, and 10 (Kishida 
et al., 2014), should be conducted in this population in order 
to identify additional MEFV mutations. 
It is important, however, to note that researchers have 
shown that about 25% of the patients carry only one MEFV 
mutation (Ozen, 2009), and up to 20% harbor no MEFV 
mutation at all (Booty et al., 2009; Touitou, 2013).  
In conclusion, the four tested MEFV mutations accounted 
for about 37% of FMF chromosomes in the Palestinian FMF-
diagnosed patients. Screening FMF-diagnosed patients for 
those mutations should constitute part of the standard 
screening for the investigated population. Testing for MEFV 
p.M680I mutation and sequencing the MEFV mutation-prone 
exons will identify additional mutations.  
 
References 
[1] Aksentijevich I, Torosyan Y, Samules J, Centola M, Pras E, 
Chae J. Mutation and haplotype studies of familial 
Mediterranean fever reveal new ancestral relationships and 
evidence for a high carrier frequency with reduced penetrance 
in the Ashkenazi Jewish population. Am J Hum Genet. 1999; 
64(4): 949–962. 
[2] Ayesh SK, Nassar SM, Al-Sharef WA, Abu-Libdeh BY, 
Darwish HM. Genetic screening of familial Mediterranean 
fever mutations in the Palestinian population. Saudi Med J. 
2005; 26(5): 732-737. 
[3] Balci B, Tinaztepe K., Yilmaz E, Gucer S, Ozen S, Topaloglu 
R, Besbas N, Ozguc M¸ Bakkaloglu A. MEFV gene mutations 
in familial Mediterranean fever phenotype II patients with 
renal amyloidosis in childhood: a retrospective 
clinicopathological and molecular study. Nephrol Dial 
Transplant 2002; 17: 1921–1923. 
[4] Belmahi L, Cherkaoui IJ, Hama I, Sefiani A. MEFV mutations 
in Moroccan patients suffering from familial Mediterranean 
fever. Rheumatol Int. 2012; 32:981–984. 
[5] Ben Chetrit, E., S. Urieli Shoval, S. Calko, D. Abeliovich, Y. 
Matzner. Molecular diagnosis of FMF. Lessons from a study 
of 446 unrelated individuals. Clin. Exp. Rheumatol. 2002; 20: 
S25-29. 
[6] Booty MG, Chae JJ, Masters SL, Remmers EF, Barham B, Le 
JM, Barron KS, Holland SM, Kastner DL, Aksentijevich I. 
Familial Mediterranean fever with a single MEFV mutation. 
Where is the second hit? Arthritis Rheum. 2009; 60(6): 1851–
1861. 
[7] Ece A, Cakmak E, Uluca U, Kelekci S. The MEFV mutations 
and their clinical correlations in children with familial 
Mediterranean fever in southeast Turkey. Rheumatol Int. 2014; 
34(2): 207-212. 
[8] Kishida D, Nakamura A, Yazaki M, Tsuchiya-Suzuki A, 
Matsuda M, Ikeda S. Genotype-phenotype correlation in 
Japanese patients with familial Mediterranean fever: 
differences in genotype and clinical features between Japanese 
and Mediterranean populations. Arthritis Res Ther. 2014; 
16:439-448. 
[9] Livneh A, Langevitz P, Shinar Y, et al. MEFV mutation 
analysis in patients suffering from amyloidosis of familial 
Mediterranean fever. Amyloid 1999; 6:1–6. 
[10] Majeed HA, El-Shanti H, Al-Khateeb MS, Abu Rabaiha Z. 
Genotype/phenotype correlations in Arab patients with 
familial Mediterranean fever. Semin Arthritis Rheum. 2002; 
31(6): 371-376. 
[11] Medlej-Hashim M, Serre JL, Corbani S, Saab O, Jalkh N, 
Delague V, Chouery E, Salem S, Loiselet J, Lefranc G, 
Megarbane A. Familial Mediterranean fever (FMF) in 
Lebanon and Jordan: a population genetics study and report of 
three novel mutations. Eur J Med Genet. 2005; 48:412–420. 
[12] Mohammadnejad L, Farajnia S. Mediterranean fever gene 
analysis in the Azeri Turk population with familial 
Mediterranean fever: evidence for new mutations associated 
with disease. Cell J. 2013; 15(2): 152-159. 
[13] Ozen S. Renal amyloidosis in familial Mediterranean fever. 
Kidney Int. 2004; 65, 1118–1127. 
[14] Ozen S. Changing concepts in familial Mediterranean fever: is 
it possible to have an autosomal-recessive disease with only 
one mutation? Arthritis Rheum. 2009; 60(6): 1575–1577. 
[15] Sarı I, Birlik M, Kasifoğlu T. Familial Mediterranean fever: 
An updated review. Eur J Rheum 2014; 1: 21-33. 
[16] Shohat M and Halpern G. Familial Mediterranean fever—A 
review. Genet Med. 2011; 13: 487–498. 
[17] Solak M, Yildiz H, Koken R, Erdogan M, Eser B, Sen T, 
Evirgen N, Erdem S, Arikan E. Analysis of familial 
Mediterranean fever gene mutations in 202 patients with 
familial Mediterranean fever. Genet Test. 2008; 12(3): 341-
344. 
[18] Touitou I. The spectrum of Familial Mediterranean Fever 
(FMF) mutations Eur J Hum Genet. 2001; 9: 473-483. 
[19] Touitou I, Lesage S, McDermott M, Cuisset L, Hoffman H, 
Dode C, et al. Infevers: an evolving mutation database for 
autoinflammatory syndromes. Hum Mutat. 2004; 24: 194–198. 
[20] Touitou I. Inheritance of autoinflammatory diseases: shifting 
paradigms and nomenclature. J Med Genet. 2013;50(6):349–
59. 
[21] Uluca U, Ece A, Sen V, Coskun S, Gunes A, Yel S, Tan I, 
Karabel M, Sahin C. High frequency of E148Q sequence 
variation in children with familial Mediterranean fever in 
southeast Turkey. Arch Argent Pediatr. 2015; 113(2): 133-139. 
[22] Yigit S, Bagci H, Ozkaya O, Ozdamar K, Cengiz K, Akpolat T. 
MEFV Mutations in Patients with Familial Mediterranean 
Fever in the Black Sea Region of Turkey. The J. Rheumatol. 
2008; 35:1. 
 
